Oncology Venture
Hej på berget
Vi har en fest her i OV
https://www.avanza.se/placera/forum/forum/oncology-venture.html
https://www.facebook.com/groups/aktieraketer/
Vi har en fest her i OV
https://www.avanza.se/placera/forum/forum/oncology-venture.html
https://www.facebook.com/groups/aktieraketer/
https://www.facebook.com/oncologyventure/
Bedste info om OV findes i facebook gruppen
Oncology Venture A/S shareholders
Bedste info om OV findes i facebook gruppen
Oncology Venture A/S shareholders
26.8.2020, 08:30 · GlobeNewswire
Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies
-Company to advance Stenoparib into human clinical trials as a potential therapy
for COVID-19
-Company provides updates on prioritized Stenoparib program in
Ovarian cancer
Hørsholm, Denmark (26 August 2020) – Oncology Venture A/S today announced that its PARP inhibitor Stenoparib (formerly known as 2X-121) has shown in vitro anti-viral activity against Coronavirus in pre-clinical studies conducted at the Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease test center. Based on these findings, Oncology Venture plans to advance the compound into human clinical trials as a potential therapy for COVID-19. Stenoparib (2X-121) is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells, currently being evaluated for cancer.
Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies
-Company to advance Stenoparib into human clinical trials as a potential therapy
for COVID-19
-Company provides updates on prioritized Stenoparib program in
Ovarian cancer
Hørsholm, Denmark (26 August 2020) – Oncology Venture A/S today announced that its PARP inhibitor Stenoparib (formerly known as 2X-121) has shown in vitro anti-viral activity against Coronavirus in pre-clinical studies conducted at the Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease test center. Based on these findings, Oncology Venture plans to advance the compound into human clinical trials as a potential therapy for COVID-19. Stenoparib (2X-121) is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells, currently being evaluated for cancer.